<DOC>
	<DOCNO>NCT00983658</DOCNO>
	<brief_summary>This Phase II , double-blind , placebo-controlled , randomize , parallel-group study design evaluate efficacy , safety , tolerability huMAb OX40L administer patient IV infusion treatment allergen-induced asthma .</brief_summary>
	<brief_title>A Study huMAb OX40L Prevention Allergen-Induced Airway Obstruction Adults With Mild Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Airway Obstruction</mesh_term>
	<criteria>Weight 50 125 kg Mild , stable allergic asthma History episodic wheeze shortness breath FEV1 baseline ≥ 70 % predict value For woman childbearing potential , agreement use effective mean contraception enrol study For men partner childbearing potential , willingness use condom spermicide treatment Ability comprehend follow require study procedure Positive skin prick test common aeroallergens ( e.g. , cat , dust , mite , grass , pollen ) Positive allergeninduced early late airway bronchoconstriction A worsening asthma respiratory tract infection within 6 week precede study entry Acute infection ( include viral infection ) within 6 week precede dosing ( 8 week respiratory infection ) ongoing chronic infection History recurrent bacterial infection adult history presence chronic infectious condition , include ( limited ) , tuberculosis , parasitic infection , etc . Lung disease mild allergic asthma History heart , lung , kidney , liver , neurologic chronic infectious disease Concomitant disease condition , could interfere conduct study , include , limited , cancer , alcoholism , drug dependency abuse , psychiatric disease History serious adverse reaction hypersensitivity drug Pregnancy lactation positive serum pregnancy test screen Chronic use medication treatment allergic lung disease shortacting β2agonists ipratropium bromide Current ( history ) treatment monoclonal antibody chimeric biomolecule within past 5 month ( 5 halflives drug ) , include omalizumab Regular use tobacco product kind within previous 6 month , smoke history &gt; 10 packyears</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Anti-OX40L</keyword>
	<keyword>Mild Allergic Asthma</keyword>
	<keyword>Allergies</keyword>
	<keyword>Allergic Asthma</keyword>
	<keyword>Adult Asthma</keyword>
</DOC>